Difference between revisions of "Part:BBa K3182103"
Line 29: | Line 29: | ||
[[File:T--Linkoping_Sweden--fitness.png|600px|thumb|center|<b>Figure B.</b>]] | [[File:T--Linkoping_Sweden--fitness.png|600px|thumb|center|<b>Figure B.</b>]] | ||
<h2>Antimicrobial activity of PlyF307-muta1</h2> | <h2>Antimicrobial activity of PlyF307-muta1</h2> | ||
− | [[File:T--Linkoping_Sweden--CBDPLYF.png| | + | [[File:T--Linkoping_Sweden--CBDPLYF.png|420px|thumb|left|<b>Figure B.</b>]] |
− | [[File:T--Linkoping_Sweden--CBD-PlyF307.png| | + | [[File:T--Linkoping_Sweden--CBD-PlyF307.png|420px|thumb|right|<b>Figure B.</b>]] |
Revision as of 18:12, 23 August 2019
Contents
Sequence and Features
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21INCOMPATIBLE WITH RFC[21]Illegal BamHI site found at 580
- 23COMPATIBLE WITH RFC[23]
- 25COMPATIBLE WITH RFC[25]
- 1000COMPATIBLE WITH RFC[1000]
Introduction
pT7-CBDcipA-PlyF307-SQ8C This part consists of a cellulose binding domain (CBD) from Clostridium thermocellum cellulose scaffolding protein (CipA) and is a central part Clostridium thermocellum's cellusome. The CBD was fused to sfGFP in this part to easily track the binding capacities and to test our release mechanism. The CBD-fusion were fused using a flexible GS-linker (-GGGGSGGGGS-). A thrombin cleavage site (-LVPRGS-) was added to the end of the linker and its breakage will leave a glycine and serine attached to the N-terminal of the fusion protein.
An internal BamHI recognition sequence (RS) has been added to enable changeable fusion proteins. BamHI was chosen because its RS codes for glycine and serine, fitting it to the end of the thrombin site. It is also cost-effective enzyme and is unaffected by methylated DNA.
Acineto phage muramidase
Fused to the CBD in this part is an endolysin from the Acineto phage, PlyF307, which is classified as a cell-wall hydrolase. Fused to the endolysin is an antimicrobial peptide from the hepatitis B virus. The version of this protein were inspired by [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4862495/ Thandar et al. 2016]. The endolysin is designed to battle the Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter spp. family of pathogens (ESKAPE). ESKAPE is a family(ies) of bacteria which has multiple understrains that has evolved resistance to the most commonly used antibiotics.
CBDcipA and Acinetobacter phage muramidase crystal structure
Expression system
The part has a very strong expression with a T7 promotor (BBa_I719005) as well as a 5'-UTR (BBa_K1758100) region which has been shown to further increase expression in E. coli (BBa_K1758106), ([http://www.ncbi.nlm.nih.gov/pubmed/2676996 Olins et al. 1989]), ([http://www.ncbi.nlm.nih.gov/pubmed/23927491 Takahashi et al. 2013]). Both this part and the part were sfGFP was changed for AsPink (BBa_K3182000) showed great expression.
Usage and Biology
Fitness cost of expression for PlyF307-muta1
Antimicrobial activity of PlyF307-muta1